IMpassion031: Results from a Phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
IMpassion031 is a global, phase III, multicentre, double-blind, randomised, placebo-controlled study in patients with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadjuvant atezolizumab or placebo with nab-paclitaxel followed by atezolizumab or placebo with dose-dense doxorubicin + cyclophosphamide. Here, we report the primary analysis of IMpassion031.
Patient (pt) preference for the pertuzumab–trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
PHranceSCa is a phase II study evaluating patient preference for the fixed-dose combination of PERJETA and Herceptin for subcutaneous injection versus PERJETA and Herceptin intravenous infusions in patients with HER2-positive early breast cancer. The current mini-oral will present patient preference and satisfaction data, along with healthcare professional perception and safety data (including when switching formulations), from the primary analysis.
IMpassion130: Final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in patients with previously untreated locally advanced or metastatic triple-negative breast cancer
IMpassion130 is a Phase III study evaluating atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in PD-L1+ metastatic triple-negative breast cancer. Here we report prespecified final OS and long-term safety results.
Ipatasertib + paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: Primary results from Cohort B of the IPATunity130 randomised trial
Cohort B of the randomised phase III IPATunity130 trial evaluated the effect of combining the oral AKT inhibitor ipatasertib with paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer requiring chemotherapy. Results of the primary analysis of Cohort B are reported in a mini oral presentation at ESMO.
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of 1st-line paclitaxel ± atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
IMpassion131 is a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel ± atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Here we report primary analysis of IMpassion131.
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy ∓ atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
IMagyn050 is a phase 3 study investigating the efficacy and safety of atezolizumab▼ versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab▼ to patients with newly-diagnosed stage III or stage IV ovarian cancer. In the current presentation, the co-primary endpoints of the study (PFS and OS in the ITT and PD-L1+ populations) are presented.